Buy Retatrutide 10mg Pen in Dubai — from AED 600

Retatrutide 10mg pen is currently in stock. This page covers FlexiPen reference details and pricing: AED 700 single, AED 650/pen at 2-pack, AED 600/pen at 5+ pack.

Retatrutide 10mg Pen is currently in stock. Remy Peptides lists stocked retatrutide formats from Pinnacle Building, Al Barsha 1, Dubai with verified contact channels at contact verification.

Current pricing is AED 600/pen (5+ pack), AED 650/pen (2-pack), AED 700 for a single pen. The 10mg pen is currently in stock.

Retatrutide 10mg Pen is currently in stock at Remy Peptides.

Yes, for in-vitro laboratory research only under UAE MoHAP Circular 17/2022. Not approved for human or veterinary use.

Retatrutide (LY-3437943) is a novel synthetic triple-agonist peptide developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. Activity at GIP receptors extends the GLP-1 and GIP framework across multiple metabolic pathways, positioning retatrutide beyond dual-agonist designs such as tirzepatide. It is the first compound to target all three metabolic pathways in a single molecule. In the 48-week Phase 2 trial (n=338), the highest-dose cohort achieved 24.2% mean body weight reduction. CAS: 2381089-83-2.

Our peptides are produced by a GMP-certified manufacturing partner using fully automated synthesis equipment and advanced analytical instruments, including UPLC and high-resolution mass spectrometry. Every batch is then independently verified by Janoshik Analytical before release, so you rely on third-party data rather than vendor-only claims. Supplied for research use only.

Semaglutide is a single-agonist (GLP-1 only). Tirzepatide is a dual-agonist (GLP-1 + GIP). Retatrutide is the first triple-agonist — activating GLP-1 for satiety signalling and delayed gastric emptying, GIP for insulin secretion and improved insulin sensitivity, and glucagon for hepatic energy expenditure, glucose regulation, and thermogenesis. This three-pathway approach addresses both energy intake and expenditure simultaneously in research models.

Current pricing is AED 700 per pen (single), AED 1,300 for a 2-pack (AED 650/pen), and AED 3,000 for a 5+ pack (AED 600/pen). The 10mg pen is currently in stock.

Store at +2 to +8°C (refrigerated) when supplied. Do not freeze. The pen is pre-filled and does not use lyophilized powder, so it needs no reconstitution or bacteriostatic water — unlike the vial formats. Each pen contains 10mg of Retatrutide delivered as 300 clicks at 0.033mg per click. The 10mg pen is currently in stock.

The pivotal Phase 2 trial was published in the New England Journal of Medicine (2023). 338 adults with obesity (BMI ≥30) were randomised across multiple dose cohorts over 48 weeks. The highest-dose group achieved 24.2% mean body weight reduction. 100% of participants in that cohort achieved ≥5% weight loss by week 24. Secondary endpoints showed significant reductions in liver fat content, improved glycemic markers, and favourable shifts in body composition (fat mass and lean mass). Across clinical studies of obesity and diabetes, published retatrutide research remains centered on investigational use.

Retatrutide is available in Dubai and across the UAE under UAE MoHAP Circular 17/2022 governing research-use compounds. It is not approved for human consumption, therapeutic use, or veterinary use. See our UAE research peptide compliance guide for full detail, or the Retatrutide UAE formats page for all formats and pricing.

30 clicks. Each click on the 10mg pen delivers 0.033mg, so 30 × 0.033mg = ~1mg.

60 clicks. 60 × 0.033mg = ~2mg on the 10mg pen.

75 clicks. 75 × 0.033mg = ~2.5mg on the 10mg pen.

300 clicks total. The 10mg pen contains 300 × 0.033mg = ~10mg of Retatrutide. See the calculator for any custom dose.

Remy Peptides lists Retatrutide 10mg Pen from Dubai (Pinnacle Building, Al Barsha 1), but this format is currently in stock.

AED 600–700 per pen, with volume tiers shown on the product page. Pricing valid through 2026-12-31.

A per-batch Certificate of Analysis ships with every order when published for this format; batch-specific publication for the 10mg pen format is pending.

Yes. Retatrutide 10mg Pen is supplied strictly for in-vitro laboratory research under UAE MoHAP Circular 17/2022. Not for human or veterinary use.